RESUMO
Abstract A collaborative physician-pharmacist relationship is a fundamental component of a patient's primary care. The aim of this study was to investigate the attitude of physicians toward collaborative work with community pharmacists in Sulaimani City, Iraq. A cross sectional design was utilized, and a questionnaire was sent to 60 physicians, of whom 47 completed the questionnaire. A total of 26 (55.3%) physicians stated that they had a history of collaboration with pharmacists in their routine daily work. During/before the treatment process, more than one-third of the physicians "rarely" practiced collaboratively, and one-fifth "never" collaborated. There was little agreement on the community pharmacist's recommendations; however, after the treatment decision by the physician, a higher degree of agreement was reported, and the number of physicians who were "rarely" or "never" practiced collaboratively decreased to less than 5%. Furthermore, the physicians' perspective on the pharmacists' role showed that advising patients on drug administration (85.1%) and preventing drug interactions (76.6%) were the most common duties of the community pharmacists. Physicians agreed on several barriers with respect to collaboration with pharmacists. In conclusion, the physicians' perspective on the engagement of the community pharmacist in the management of patients was relatively limited. The pharmacist's recommendation was more accepted after medications were prescribed than before or during decision making on the treatment.
RESUMO
The present study aimed to evaluate the effect of the adjuvant use of resveratrol with meloxicam on the clinical scores of knee OA patients. This was a double-blind placebo-controlled randomised trial involving 100 patients with knee osteoarthritis performed at the Shar Teaching Hospital, Sulaimani General Hospital and Specialised Rheumatology Center, Sulaimani City from December 2016 to September 2017. The efficacy of the treatment was evaluated by measuring the changes from baseline in the KOOS score, WOMAC index, and VAS-100 score after 90 days of treatment. Resveratrol significantly improves the knee OA pain and associated symptoms compared with placebo, and both clinical scores were found to be eligible for following treatment outcomes. In conclusion, resveratrol, when used in combination with meloxicam, improves pain and symptom scores in patients with mild-to-moderate knee OA compared with placebo. The intervention with a dietary supplement may significantly impact the pain and overall quality of life in patients with knee OA.